The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Issue 3 (23rd May 2013)

• Record Type: Journal Article
• Authors: Bajaj, Jasmohan S.; Thacker, Leroy R.; Heuman, Douglas M.; Fuchs, Michael; Sterling, Richard K.; Sanyal, Arun J.; Puri, Puneet; Siddiqui, Mohammad S.; Stravitz, Richard T.; Bouneva, Iliana; Luketic, Velimir; Noble, Nicole; White, Melanie B.; Monteith, Pamela; Unser, Ariel; Wade, James B.
• Is Part Of: Hepatology. Volume 58:Issue 3(2013:Sep.)
• Page Start: 1122
• Page End: 1132
• Publication Date: 2013-05-23
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.26309
• Languages: English
• ISSNs: 0270-9139

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Minimal hepatic encephalopathy (MHE) detection is difficult because of the unavailability of short screening tools. Therefore, MHE patients can remain undiagnosed and untreated. The aim of this study was to use a Stroop smartphone application (app) (EncephalApp_Stroop) to screen for MHE. The app and standard psychometric tests (SPTs; 2 of 4 abnormal is MHE, gold standard), psychometric hepatic encephalopathy score (PHES), and inhibitory control tests (ICTs) were administered to patients with cirrhosis (with or without previous overt hepatic encephalopathy; OHE) and age‐matched controls from two centers; a subset underwent retesting. A separate validation cohort was also recruited. Stroop has an "off" state with neutral stimuli and an "on" state with incongruent stimuli. Outcomes included time to complete five correct runs as well as number of trials needed in on (Ontime) and off (Offtime) states. Stroop results were compared between controls and patients with cirrhosis with or without OHE and those with or without MHE (using SPTs, ICTs, and PHES). Receiver operating characteristic analysis was performed to diagnose MHE in patients with cirrhosis with or without previous OHE. One hundred and twenty‐five patients with cirrhosis (43 previous OHE) and 134 controls were included in the original cohort. App times were correlated with Model for End‐Stage Liver Disease (Offtime: <italic>r</italic> = 0.57; Ontime: <italic>r</italic> = 0.61; <italic>P</italic> < 0.0001) and were worst in previous OHE patients, compared to the rest and controls. Stroop performance was also significantly impaired in those with MHE, compared to those without MHE, according to SPTs, ICTs, and PHES (all <italic>P</italic> < 0.0001). A cutoff of >274.9 seconds (Ontime plus Offtime) had an area under the curve of 0.89 in all patients and 0.84 in patients without previous OHE for MHE diagnosis using SPT as the gold standard. The validation cohort showed 78% sensitivity and 90% specificity with the >274.9‐seconds Ontime plus Offtime cutoff. App result patterns were similar between the centers. Test‐retest reliability in controls and those without previous OHE was good; a learning effect on Ontime in patients with cirrhosis without previous OHE was noted. <italic>Conclusion:</italic> The Stroop smartphone app is a short, valid, and reliable tool for screening of MHE. (H<sc>epatology</sc> 2013;58:1122‐1132)</p> </abstract>